Senate Bill Would End Federal Prohibition on Medical Marijuana
MARCH 11TH, 2015
A bill introduced Tuesday by three U.S. senators would end the federal prohibition on medical marijuana, The Washington Post reports.The bill was introduced by Cory Booker of New Jersey and Kirsten Gillibrand of New York, both Democrats, and Rand Paul of Kentucky, a Republican.
The Compassionate Access, Research Expansion and Respect States (CARERS) Act, would reclassify marijuana from Schedule I to Schedule II under the Controlled Substances Act. Schedule I drugs, which include heroin, have no accepted medical use in the United States. Schedule II drugs have a legitimate medical use but also have a high potential for abuse.
The bill would permit Veterans Affairs doctors to prescribe medical marijuana to veterans, and would make it easier for scientists to obtain marijuana for medical research. It would allow banks and credit unions to provide the same services to the marijuana industry as they do to other businesses, without the fear of federal prosecution or investigation, the article notes.
Because marijuana is still illegal under federal law, banks have been reluctant to conduct business with marijuana-related companies. Banks have feared being accused of helping these businesses launder their money.
The measure would not legalize medical marijuana in all 50 states, but would prevent federal law enforcement from prosecuting patients, doctors and caregivers in states that have their own medical marijuana programs. Currently 23 states plus the District of Columbia have legalized medical marijuana.
An additional 12 states have approved use of marijuana strains with high levels of cannabidiol (CBD), which does not produce the high associated with the drug, and is used to treat epileptic seizures. The measure would remove specific strains of CBD oil from the federal definition of marijuana, to allow its use in treatment of intractable seizures.
The bill’s fate in the Senate is unclear.
/By JOIN TOGETHER STAFF
The FDA recently voted in favor of pushing a new formulation of oxycodone hydrochloride for approval. The new OxyContin formula is more difficult to crush or dissolve which will hopefully make it harder to be used as a drug of abuse . The FDA recommended that Purdue Pharma's application for a new, resin-coated formulation should replace the original version, which has been on the market since 1996. Randall Flick, MD, an anesthesiologist at the Mayo Clinic who voted to recommend approval of the drug said, "Clearly the old formulation is worse than the new, although I think the difference is relatively small," Flick concluded, "Hardcore abusers are likely to devise new ways to break down the harder tablet or figure out which solvents will dissolve it fastest, within 'day or weeks' of the product's release on the market."